CNBC's "Fast Money" Big Pharma Breakout… And A Billionaire Boycott On Netflix 10/1/25
21 snips
Oct 1, 2025 Pharma stocks are on the rise after a significant drug pricing deal, signaling optimism in the healthcare sector. The hosts analyze technical indicators that suggest a bullish trend for major companies like Pfizer and Merck. Meanwhile, Elon Musk stirs controversy by encouraging Netflix users to cancel subscriptions, raising questions about content creation and subscriber loyalty. The discussion also touches on the broader market outlook, with S&P hitting new highs, and advice for young professionals on work-life balance.
AI Snips
Chapters
Transcript
Episode notes
Underweight Positioning Supports Rally
- Health care positioning is very underweight, which supports sustainability of any rally.
- Low Medicare exposure for many pharma companies makes negotiated pricing less damaging than headlines imply.
Deals Add Real Pipeline Momentum
- Pipeline-strengthening deals (e.g., Metsera acquisition) add conviction beyond policy headlines.
- Such corporate actions can independently re-rate companies like Pfizer even amid patent-cliff concerns.
Technical Breakouts In Beaten-Up Names
- The S&P pharma sub-industry has been deeply underperforming and is now showing technical breakouts after months of basing.
- Early-volume confirmation suggests further upside of 10-15% in bombed-out names is plausible.